{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-078800","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.240396+00:00","generated_at":"2026-06-04T07:17:20.282115+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Mereo BioPharma reports FY2023 revenue $10M, net loss $29.5M; cash $57.4M funds ops into 2026","bullets":["Revenue $10.0M from Ultragenyx milestone and ReproNovo upfront; net loss $29.5M vs $42.2M in 2022.","Cash $57.4M; net cash burn Q4 2023 $6.7M; expected runway into 2026 supporting current plans.","Setrusumab Orbit (Phase 2/3) enrollment completes Q1 2024; Cosmic (Phase 3) H1 2024, by partner Ultragenyx.","Alvelestat Phase 3 plan with partner around end 2024; FDA aligned on SGRQ primary endpoint.","Leflutrozole licensed to ReproNovo for up to $64.25M milestones plus tiered mid-single digit royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-078800","json":"https://secwatch.observer/filing/0001193125-24-078800.json","markdown":"https://secwatch.observer/filing/0001193125-24-078800.md","text":"https://secwatch.observer/filing/0001193125-24-078800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524078800/0001193125-24-078800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524078800/d807451d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:17:20.282115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54b81581301ac04cc59be9280fc8489dfe2d6f5d","claim":"Mereo BioPharma Group plc reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On March 27, 2024, Mereo BioPharma Group plc announced its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524078800/0001193125-24-078800-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}